Which one of the following companies will be the f
Post# of 158778
(Total Views: 720)
Posted On: 11/16/2025 2:41:39 PM
Which one of the following companies will be the first to break and start the bidding
when they realize that they will be left out in the cold from the cancer tumor treatment industry if they don't acquire Leronlimab?
As of November 2025, there are 10 major pharmaceutical companies manufacturing FDA-approved immune checkpoint inhibitors (ICIs), which are primarily monoclonal antibodies targeting PD-1, PD-L1, CTLA-4, and LAG-3. These companies produce the 13 currently approved ICIs in the US. Here's a breakdown based on recent data:
Bristol-Myers Squibb: Produces nivolumab (Opdivo), ipilimumab (Yervoy), and relatlimab (in Opdualag).
Merck & Co.: Produces pembrolizumab (Keytruda).
Roche/Genentech: Produces atezolizumab (Tecentriq).
AstraZeneca: Produces durvalumab (Imfinzi) and tremelimumab (Imjudo).
Pfizer: Produces avelumab (Bavencio, co-developed with Merck KGaA).
Regeneron Pharmaceuticals (with Sanofi): Produces cemiplimab (Libtayo).
GlaxoSmithKline (GSK): Produces dostarlimab (Jemperli).
Incyte Corporation: Produces retifanlimab (Zynyz).
BeiGene: Produces tislelizumab (Tevimbra).
Coherus BioSciences: Produces toripalimab (Loqtorzi, with rights from Shanghai Junshi Biosciences).
This count focuses on primary manufacturers of approved products; partnerships are noted but counted as one entity per lead developer.393091 Globally, the number could be higher (up to 15–20 including China-approved ICIs from firms like Innovent Biologics), but US approvals represent the core commercial manufacturing landscape.
when they realize that they will be left out in the cold from the cancer tumor treatment industry if they don't acquire Leronlimab?
As of November 2025, there are 10 major pharmaceutical companies manufacturing FDA-approved immune checkpoint inhibitors (ICIs), which are primarily monoclonal antibodies targeting PD-1, PD-L1, CTLA-4, and LAG-3. These companies produce the 13 currently approved ICIs in the US. Here's a breakdown based on recent data:
Bristol-Myers Squibb: Produces nivolumab (Opdivo), ipilimumab (Yervoy), and relatlimab (in Opdualag).
Merck & Co.: Produces pembrolizumab (Keytruda).
Roche/Genentech: Produces atezolizumab (Tecentriq).
AstraZeneca: Produces durvalumab (Imfinzi) and tremelimumab (Imjudo).
Pfizer: Produces avelumab (Bavencio, co-developed with Merck KGaA).
Regeneron Pharmaceuticals (with Sanofi): Produces cemiplimab (Libtayo).
GlaxoSmithKline (GSK): Produces dostarlimab (Jemperli).
Incyte Corporation: Produces retifanlimab (Zynyz).
BeiGene: Produces tislelizumab (Tevimbra).
Coherus BioSciences: Produces toripalimab (Loqtorzi, with rights from Shanghai Junshi Biosciences).
This count focuses on primary manufacturers of approved products; partnerships are noted but counted as one entity per lead developer.393091 Globally, the number could be higher (up to 15–20 including China-approved ICIs from firms like Innovent Biologics), but US approvals represent the core commercial manufacturing landscape.
(17)
(0)